Veru Inc. – Company Overview and Recent Market Activity
Company Identification
- Name: Veru Inc.
- Sector: Health Care
- Industry: Personal Care Products
- Primary Exchange: Nasdaq
- Currency: USD
Financial Snapshot (as of 2025‑11‑20)
- Close Price: $2.22 per share
- 52‑Week High: $14.20 (dated 2025‑01‑23)
- 52‑Week Low: $2.11 (dated 2025‑11‑19)
- Market Capitalization: $35,630,000
- Price‑Earnings Ratio: –1.13
Corporate Profile Veru Inc. is a biopharmaceutical company headquartered in Miami, Florida. The company focuses on the development of medications for prostate cancer treatment, supportive care for prostate cancer patients, and other urology specialty pharmaceuticals.
Recent News Coverage
No news items directly referencing Veru Inc. were identified in the provided data for the period up to 2025‑11‑23. The available news entries concern:
- A sports match in the Norwegian Premier League, reported by keldan.is (source: fótbolti.net).
- A real‑estate market analysis in Slovakia, reported by plus7dni.pluska.sk.
- A political‑economic development in Serbia regarding the National Oil Industry (NIS), reported by biznis.telegraf.rs.
These reports contain no information about Veru Inc.’s operations, financial performance, regulatory filings, or corporate actions. Therefore, the company’s recent public disclosures and market activity remain unchanged from the last available data snapshot.
Implications for Investors
- Valuation: With a negative P/E ratio, the company is currently trading at a valuation that suggests earnings are not yet positive or are heavily discounted by market expectations.
- Price Volatility: The stock has experienced a substantial decline from its 52‑week high to its 52‑week low, indicating heightened volatility and potential risk for equity holders.
- Liquidity and Market Presence: A market cap of approximately $35.6 million positions Veru Inc. as a small‑cap entity within the Nasdaq ecosystem.
Investors should monitor forthcoming regulatory filings, clinical trial milestones, and partnership announcements to gauge future upside potential. In the absence of recent news, the company’s trajectory will largely depend on its internal development pipeline and the broader biopharmaceutical market dynamics.
